
1. j clin oncol. 2016 apr 20;34(12):1300-8. doi: 10.1200/jco.2015.62.5970. epub 2015
dec 28.

association human papillomavirus p16 status outcomes imcl-9815
phase iii registration trial patients locoregionally advanced
oropharyngeal squamous cell carcinoma head neck treated with
radiotherapy without cetuximab.

rosenthal di(1), harari pm(1), giralt j(1), bell d(1), raben d(1), liu j(1),
schulten j(1), ang kk(1), bonner ja(2).

author information: 
(1)david i. rosenthal, diana bell, kian k. ang, university texas md
anderson cancer center, houston, tx; paul m. harari, university wisconsin,
madison, wi; jordi giralt, hospital vall d'hebron, barcelona, spain; david raben,
university colorado school medicine, aurora, co; joyce liu, merck serono,
beijing, people's republic china; jeltje schulten, merck kgaa, darmstadt,
germany; james a. bonner, university alabama birmingham comprehensive
cancer center, birmingham, al.
(2)david i. rosenthal, diana bell, kian k. ang, university texas md
anderson cancer center, houston, tx; paul m. harari, university wisconsin,
madison, wi; jordi giralt, hospital vall d'hebron, barcelona, spain; david raben,
university colorado school medicine, aurora, co; joyce liu, merck serono,
beijing, people's republic china; jeltje schulten, merck kgaa, darmstadt,
germany; james a. bonner, university alabama birmingham comprehensive
cancer center, birmingham, al. jabonner@uabmc.edu.

comment in
    j clin oncol. 2016 apr 20;34(12):1289-91.

purpose: conducted retrospective evaluation imcl-9815 study to
examine association human papillomavirus (hpv) p16 protein expression 
status outcomes patients oropharyngeal carcinoma (opc) receiving
radiotherapy (rt) plus cetuximab rt alone.
patients methods: imcl-9815 study, patients randomly allocated to
receive rt plus weekly cetuximab rt alone. subpopulation patients with
p16-evaluable opc retrospectively evaluated basis locoregional
control (lrc), overall survival (os), progression-free survival (pfs).
evaluable samples patients p16-positive opc also tested hpv
dna.
results: tumor p16 status evaluable 182 patients opc enrolled 
imcl-9815 study; 41% p16 positive. treated rt alone rt plus
cetuximab, p16-positive patients longer os p16-negative patients
(hazard ratio, 0.40; 95% ci, 0.21 0.74 hazard ratio, 0.16; 95% ci, 0.07 to
0.36, respectively). addition cetuximab rt increased lrc, os, pfs
in patients p16-positive opc p16-negative disease.
interaction tests lrc, os, pfs demonstrate significant
interaction p16 status treatment effect (p = .087, .085, .253,
respectively). similar trends observed patients with
p16-positive/hpv-positive opc (n = 49) p16-positive/hpv-negative
opc (n = 14) compared.
conclusion: p16 status strongly prognostic patients opc. data
suggest addition cetuximab rt improved clinical outcomes
regardless p16 hpv status versus rt alone.

© 2015 american society clinical oncology.

doi: 10.1200/jco.2015.62.5970 
pmcid: pmc5070577
pmid: 26712222  [indexed medline]

conflict interest statement: authors’ disclosures potential conflicts of
interest found article online www.jco.org. author contributions are
found end article.

